Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study

✍ Scribed by Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lubansky; Fausto Grignani

• Publisher: John Wiley and Sons
• Year: 1986
• Tongue: English
• Weight: 192 KB
• Volume: 58
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19860901)58:5<1018::aid-cncr2820580505>3.0.co;2-q

✦ Synopsis

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding group was 514 days. Toxic effects included moderate hematologic toxicity, nausea, and vomiting. There were no treatment-related deaths. This regimen clearly is effective in treating NSCL.